Background: The pathogenesis of inflammatory bowel disease is complex and multifactorial. Studies have led to the current concept that aryl hydrocarbon receptors have recently emerged as a critical physiological regulator of immune responses affecting both innate and adaptive systems. We studied the possibility of simvastatin and antagonist of receptors of interleukin-1 for pharmacological correction of colitis in rats with a focus on the expression intensity studies of AhR with lymphocytes of colon.
Methods: Experiments were carried out on male Wistar rats aged 8 months (body mass 260–285 g). Rats were divided into four experimental groups: group 1 – control; group 2 – rats with oxazolone-induced colitis; group 3 – rats given simvastatin (20 mg/kg, for 5 days, intraperitoneally); group 4 – rats given antagonist of receptors of interleukin-1 (3 mg/kg, for 5 days, subcutaneously). The AhR immunopositive lymphocytes were determined using an indirect immunofluorescence technique with using a monoclonal rat antibody.
Results: We established that development of colitis was not accompanied with the change of amount of AhR+ lymphocytes in immunopositive cells. Drug administration during the development of experimental pathology was accompanied by changes in the expression of AhR on lymphocytes.
Conclusions: Simvastatin and antagonist of receptors of interleukin-1 seemed to be beneficial in oxazolone -induced colitis rat model through modulate AhR expression with lymphocytes of colon.